Hyperuricemia drives intestinal barrier dysfunction by regulating gut microbiota

Area of Science:

• Gastroenterology
• Microbiology
• Immunology

Background:

• Hyperuricemia is known to increase gut permeability.
• The specific mechanisms by which hyperuricemia compromises the intestinal barrier remain poorly understood.

Purpose of the Study:

• To investigate the role of gut microbiota in hyperuricemia-induced intestinal barrier dysfunction.
• To identify key molecular players and therapeutic targets.

Main Methods:

• A mouse model of hyperuricemia was established using adenine and oteracil potassium.
• Treatments included allopurinol (to reduce uric acid), antibiotics (to deplete microbiota), and germ-free conditions.
• Intestinal permeability, gut microbial composition (16S rRNA sequencing), inflammatory markers (IL-1β, TNF-α), and tight junction proteins were assessed.

Main Results:

• Allopurinol reduced intestinal permeability and TNF-α levels.
• Antibiotics partially alleviated permeability, while removing gut microbiota exacerbated lipid metabolic dysfunction.
• Hyperuricemia in germ-free mice protected against intestinal injury, and treatments modulated inflammatory and tight junction gene expression.

Conclusions:

• Gut microbiota is a direct and specific contributor to intestinal barrier dysfunction in hyperuricemia.
• Targeting gut microbiota and uric acid levels shows therapeutic potential for managing hyperuricemia-related gut issues.